Strides Shasun Receives USFDA Approval for Oseltamivir Phosphate Capsules

Strides Shasun Limited announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received final approval for Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the USFDA. Oseltamivir Phosphate Capsules is a generic version of Tamiflu Capsules of Hoffmann-La Roche, Inc. Oseltamivir Phosphate Capsules registered a significant volume growth due to one of the worst flu seasons in the US last year. As per IQVIA MAT April 2018 data, the US market for Oseltamivir Phosphate Capsules was approximately USD 725 Million. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. The company has 75 cumulative ANDA filings with USFDA of which 48 ANDAs have been approved as of date and 27 are pending approval. – Medical Buyer Bureau